Screener
Dianthus Therapeutics DNTH Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other assets | (2,123) | 2,000 |
| Accounts payable, accrued expenses and operating lease liabilities | 6,999 | (1,500) |
| Deferred revenue | 849 | (57) |
| Net cash used in operating activities | (28,856) | (27,630) |
| Cash flows from investing activities: | ||
| Capital expenditures | (10) | (24) |
| Purchases of investment securities | (238,588) | (67,324) |
| Proceeds from sales and maturities of investment securities | 104,625 | 82,142 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dianthus Therapeutics's operating cash flow?
- Dianthus Therapeutics (DNTH) reported operating cash flow of -$28.86M in Q1 2026.
- How has Dianthus Therapeutics's operating cash flow changed year-over-year?
- Dianthus Therapeutics's operating cash flow decreased by 4.4% year-over-year, from -$27.63M to -$28.86M.
- What is the long-term trend for Dianthus Therapeutics's operating cash flow?
- Over 2 years (2021 to 2024), Dianthus Therapeutics's operating cash flow has grown at a 14.6% compound annual growth rate (CAGR), from -$59.53M to -$78.18M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Dianthus Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude